What Is BridgeBio Pharma, Inc. (BBIO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, BridgeBio Pharma, Inc.'s intrinsic value is estimated at $51.22. Trading at its current price of $84.09, the valuation engine raises significant caution: 6 of 8 models flag downside risk, projecting an average implied return of -39.1%. Model dispersion is worth noting: Markov DDM targets $161.95 (+92.6%), versus Regime Cross at $0.01 (-100.0%). This +192.6% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Markov DDM, FTNN lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About BBIO?
8 of 13 models are currently active for BBIO. Of these, 2 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates BBIO's intrinsic value at $27.96, implying -66.7% downside from the current price. See which stocks rank higher →
How Does BBIO Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, BBIO ranks #63 by Quality of Company score. CirclFi's QOC score of 7.0/10 evaluates 32 fundamental signals. A score of 7.0 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For BridgeBio Pharma, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is BBIO a Value Trap?
CirclFi's Value Trap algorithm assigns BBIO a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for BridgeBio Pharma, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, BridgeBio Pharma, Inc. scores 7.0 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +192.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BBIO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BBIO's 8 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad